Jeremy Deutsch, MD
Hematology & Oncology · Wichita, KSNPI 1528263043
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.9%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 13.9%. Reporting peaked in 2020 at $8,294 and has fallen 62.3% since, to $3,124 in 2025.
Across 1,043 payments — averaging $26.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- Daiichi Sankyo Inc.$2K
- Seagen Inc.$2K
- AbbVie$2K
- Novartis$1K
- Pfizer$1K
- plus $16K from 54 others
What the payments were for
- Consulting fees$9,96836%
- Speaking & faculty fees$8503%
- Food & beverage$16,77860%
- Education$4021%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$27,998 in reported general payments places this provider in the 75th percentile of 97 hematology & oncology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 95 | $1,208,912 |
| ImbruvicaIbrutinib | 42 | $702,500 |
| JakafiRuxolitinib Phosphate | 25 | $554,970 |
| RevlimidLenalidomide | 31 | $466,803 |
| IbrancePalbociclib | 25 | $394,818 |
| InrebicFedratinib Dihydrochloride | 12 | $354,966 |
| VonjoPacritinib Citrate | 12 | $316,785 |
| XtandiEnzalutamide | 28 | $316,031 |
| VenclextaVenetoclax | 24 | $289,461 |
| BrukinsaZanubrutinib | 22 | $257,386 |
| LumakrasSotorasib | 11 | $236,919 |
| Imatinib Mesylate | 24 | $55,933 |
| EliquisApixaban | 28 | $24,188 |
| XareltoRivaroxaban | 23 | $17,208 |
| Anastrozole | 767 | $9,696 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid, Inrebic | $954 | $821,76943 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $107 | $702,50042 claims |
| Incyte CorporationJakafi | $125 | $554,97025 claims |
| PfizerIbrance, Eliquis | $1,025 | $419,00653 claims |
| Astellas Pharma US IncXtandi | $550 | $316,03128 claims |
| AbbVieVenclexta | $1,543 | $289,46124 claims |
| Beigene USA, Inc.Brukinsa | $104 | $257,38622 claims |
| AmgenLumakras | $468 | $236,91911 claims |
| Johnson & JohnsonXarelto | $773 | $17,20823 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 97 hematology & oncology providers in Kansas.
Other hematology & oncology in Wichita
- Shaker DakhilWichita$579K
- Quoc TruongWichita$539K
- Bassam MattarWichita$221K
- Phu TruongWichita$73K
- Pavan ReddyWichita$65K
- Christopher DakhilWichita$59K
- Nassim NabboutWichita$28K
- Dennis MooreWichita$26K
- Seth PageWichita$18K
- Marc HoffmannOverland Park$153K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.